发明名称 TARGETED THERAPY TO RESTORE RADIOACTIVE IODINE TRANSPORT IN THYROID CANCER
摘要 The invention includes method, pharmaceutical compositions and uses thereof for treating patients with Papillary Thyroid Carcinoma (PTC) using a Platelet Derived Growth Factor Receptor Alpha (PDGFRA) inhibitor. The PDGFRA inhibitor is preferably an antibody specific to PDGFRA and causes an increase in the sensitivity level of PTC cells to radioiodine treatment. Moreover, the antibody can be used in combination with other PDGFRA inhibitors such as tyrosine kinase inhibitors and RNA interference molecules.
申请公布号 US2017037143(A1) 申请公布日期 2017.02.09
申请号 US201515304394 申请日期 2015.04.17
申请人 The Governors of the University of Alberta 发明人 MCMULLEN Todd;LOPEZ-CAMPISTROUS Ana;WILLIAMS David
分类号 C07K16/30;A61K45/06;G01N33/68;C12N15/113;A61K31/7088;A61K39/395;A61K51/00 主分类号 C07K16/30
代理机构 代理人
主权项 1. A method for treating a patient with papillary thyroid carcinoma comprising: administering a therapeutically effective amount of at least one PDGFRA inhibitor, or a pharmaceutically acceptable salt thereof, to a patient with papillary thyroid carcinoma, wherein the administering of the PDGFRA inhibitor treats or reduces the severity of papillary thyroid carcinoma symptoms.
地址 Edmonton CA